Mouse models of multiple myeloma: technologic platforms and perspectives

Marco Rossi; Cirino Botta; Mariamena Arbitrio; Rosa Daniela Grembiale; Pierosandro Tagliaferri; Pierfrancesco Tassone

doi:10.18632/oncotarget.24614

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Mouse models of multiple myeloma: technologic platforms and perspectives

Marco Rossi, Cirino Botta, Mariamena Arbitrio, Rosa Daniela Grembiale, Pierosandro Tagliaferri and Pierfrancesco Tassone _

PDF | HTML | How to cite

Oncotarget. 2018; 9:20119-20133. https://doi.org/10.18632/oncotarget.24614

Metrics: PDF 3229 views | HTML 4550 views | ?

Abstract

Marco Rossi1, Cirino Botta1, Mariamena Arbitrio1, Rosa Daniela Grembiale2, Pierosandro Tagliaferri1 and Pierfrancesco Tassone1,3

1Department of Experimental and Clinical Medicine, “Magna Graecia” University of Catanzaro, Catanzaro, Italy

2Department of Health Sciences, Magna Graecia University, Catanzaro, Italy

3Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA

Correspondence to:

Pierfrancesco Tassone, email: [email protected]

Keywords: mouse models; multiple myeloma; SCID; SCID-hu; SCID-synth-hu

Received: October 12, 2017 Accepted: February 24, 2018 Published: April 13, 2018

ABSTRACT

Murine models of human multiple myeloma (MM) are key tools for the study of disease biology as well as for investigation and selection of novel candidate therapeutics for clinical translation. In the last years, a variety of pre-clinical models have been generated to recapitulate a wide spectrum of biological features of MM. These systems range from spontaneous or transgenic models of murine MM, to subcutaneous or orthothopic xenografts of human MM cell lines in immune compromised animals, to platform allowing the engraftment of primary/bone marrow-dependent MM cells within a human bone marrow milieu to fully recapitulate human disease. Selecting the right model for specific pre-clinical research is essential for the successful completion of investigation. We here review recent and most known pre-clinical murine, transgenic and humanized models of MM, focusing on major advantages and/or weaknesses in the light of different research aims.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24614

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Mouse models of multiple myeloma: technologic platforms and perspectives

Abstract